Zanidatamab, a bispecific antibody that binds two distinct HER2 epitopes showed an ORR of 41% and a median progression-free survival of 5.5 months in 80 patients with HER2-positive CCA.231. This evidence concerns the gene ERBB2 and cholangiocarcinoma.